Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| REGENERON PHARMACEUTICALS, INC.REGN · Entity 2010 | EVP Research | December 09, 2025 | December 11, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
REGENERON PHARMACEUTICALS, INC.
Report date December 09, 2025 · Filed December 11, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 47,833 |
Reported balance
After 2025-12-09 transaction · row 1
1 source rowRow 1 · 2025-12-09 · Tax withholding · Disposed 4,229 · Balance 47,833 |
| Common StockSEC Table I · non-derivative | IndirectBy 401(k) Plan | 4,375 |
Reported balance
Holding disclosure · report date 2025-12-09 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 4,375 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 14, 2020 Filed Jul 15, 2020 20:51 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 255 | $618.39 | $157,689.45 |
DisclosureSEC source: 0001708138-20-000087 · edgardoc.xml · nonDerivative · entry 21 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,064 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F19 · price: Represents volume-weighted average price of sales of 255 shares of Company stock on July 14, 2020 at prices ranging from $618.17 to $618.55. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on July 14, 2020 at each separate price. Read SEC document |
| July 14, 2020 Filed Jul 15, 2020 20:51 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 304 | $617.64 | $187,762.56 |
DisclosureSEC source: 0001708138-20-000087 · edgardoc.xml · nonDerivative · entry 20 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,319 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F18 · price: Represents volume-weighted average price of sales of 304 shares of Company stock on July 14, 2020 at prices ranging from $617.34 to $617.86. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on July 14, 2020 at each separate price. Read SEC document |
| July 14, 2020 Filed Jul 15, 2020 20:51 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 256 | $616.34 | $157,783.04 |
DisclosureSEC source: 0001708138-20-000087 · edgardoc.xml · nonDerivative · entry 19 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,623 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F17 · price: Represents volume-weighted average price of sales of 256 shares of Company stock on July 14, 2020 at prices ranging from $616.05 to $616.85. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on July 14, 2020 at each separate price. Read SEC document |
| July 14, 2020 Filed Jul 15, 2020 20:51 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 203 | $615.59 | $124,964.77 |
DisclosureSEC source: 0001708138-20-000087 · edgardoc.xml · nonDerivative · entry 18 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,879 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F16 · price: Represents volume-weighted average price of sales of 203 shares of Company stock on July 14, 2020 at prices ranging from $615.58 to $615.59. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on July 14, 2020 at each separate price. Read SEC document |
| July 14, 2020 Filed Jul 15, 2020 20:51 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 178 | $614.62 | $109,402.36 |
DisclosureSEC source: 0001708138-20-000087 · edgardoc.xml · nonDerivative · entry 17 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,082 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F15 · price: Represents volume-weighted average price of sales of 178 shares of Company stock on July 14, 2020 at prices ranging from $614.41 to $614.84. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on July 14, 2020 at each separate price. Read SEC document |
| July 13, 2020 Filed Jul 15, 2020 20:51 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 13,000 | $0.00 Strike: $30.63 | $0.00 |
DisclosureSEC source: 0001708138-20-000088 · edgardoc.xml · derivative · entry 11 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,736 Underlying: Common Stock · 13,000 shares Expires 2020-12-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F7 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. F8 · balance_after: Form two of two Read SEC document |
| July 13, 2020 Filed Jul 15, 2020 20:51 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 6,691 | $623.98 | $4,175,050.18 |
DisclosureSEC source: 0001708138-20-000087 · edgardoc.xml · nonDerivative · entry 16 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,260 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| July 13, 2020 Filed Jul 15, 2020 20:51 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 13,000 | $30.63 | $398,190.00 |
DisclosureSEC source: 0001708138-20-000087 · edgardoc.xml · nonDerivative · entry 15 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,951 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| July 13, 2020 Filed Jul 15, 2020 20:51 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 441 | $633.28 | $279,276.48 |
DisclosureSEC source: 0001708138-20-000087 · edgardoc.xml · nonDerivative · entry 14 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,951 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F14 · price: Represents volume-weighted average price of sales of 441 shares of Company stock on July 13, 2020 at prices ranging from $633.25 to $633.29. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on July 13, 2020 at each separate price. Read SEC document |
| July 13, 2020 Filed Jul 15, 2020 20:51 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 680 | $632.65 | $430,202.00 |
DisclosureSEC source: 0001708138-20-000087 · edgardoc.xml · nonDerivative · entry 13 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,392 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F13 · price: Represents volume-weighted average price of sales of 680 shares of Company stock on July 13, 2020 at prices ranging from $632.02 to $632.96. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on July 13, 2020 at each separate price. Read SEC document |
| July 13, 2020 Filed Jul 15, 2020 20:51 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 861 | $631.45 | $543,678.45 |
DisclosureSEC source: 0001708138-20-000087 · edgardoc.xml · nonDerivative · entry 12 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,072 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F12 · price: Represents volume-weighted average price of sales of 861 shares of Company stock on July 13, 2020 at prices ranging from $631.06 to $631.91. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on July 13, 2020 at each separate price. Read SEC document |
| July 13, 2020 Filed Jul 15, 2020 20:51 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,423 | $630.50 | $897,201.50 |
DisclosureSEC source: 0001708138-20-000087 · edgardoc.xml · nonDerivative · entry 11 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,933 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F11 · price: Represents volume-weighted average price of sales of 1,423 shares of Company stock on July 13, 2020 at prices ranging from $630.06 to $630.83. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on July 13, 2020 at each separate price. Read SEC document |
| July 13, 2020 Filed Jul 15, 2020 20:51 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 883 | $629.62 | $555,954.46 |
DisclosureSEC source: 0001708138-20-000087 · edgardoc.xml · nonDerivative · entry 10 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,356 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F10 · price: Represents volume-weighted average price of sales of 883 shares of Company stock on July 13, 2020 at prices ranging from $629.05 to $629.90. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on July 13, 2020 at each separate price. Read SEC document |
| July 13, 2020 Filed Jul 15, 2020 20:51 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 259 | $628.32 | $162,734.88 |
DisclosureSEC source: 0001708138-20-000087 · edgardoc.xml · nonDerivative · entry 9 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,239 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F9 · price: Represents volume-weighted average price of sales of 259 shares of Company stock on July 13, 2020 at prices ranging from $628.20 to $628.57. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on July 13, 2020 at each separate price. Read SEC document |
| July 13, 2020 Filed Jul 15, 2020 20:51 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 657 | $627.54 | $412,293.78 |
DisclosureSEC source: 0001708138-20-000087 · edgardoc.xml · nonDerivative · entry 8 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,498 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F8 · price: Represents volume-weighted average price of sales of 657 shares of Company stock on July 13, 2020 at prices ranging from $627.00 to $627.93. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on July 13, 2020 at each separate price. Read SEC document |
| July 13, 2020 Filed Jul 15, 2020 20:51 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,003 | $626.63 | $628,509.89 |
DisclosureSEC source: 0001708138-20-000087 · edgardoc.xml · nonDerivative · entry 7 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,155 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F7 · price: Represents volume-weighted average price of sales of 1,003 shares of Company stock on July 13, 2020 at prices ranging from $626.03 to $626.88. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on July 13, 2020 at each separate price. Read SEC document |
| July 13, 2020 Filed Jul 15, 2020 20:51 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 173 | $625.86 | $108,273.78 |
DisclosureSEC source: 0001708138-20-000087 · edgardoc.xml · nonDerivative · entry 6 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,158 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F6 · price: Represents volume-weighted average price of sales of 173 shares of Company stock on July 13, 2020 at prices ranging from $625.77 to $625.96. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on July 13, 2020 at each separate price. Read SEC document |
| July 13, 2020 Filed Jul 15, 2020 20:51 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 370 | $624.47 | $231,053.90 |
DisclosureSEC source: 0001708138-20-000087 · edgardoc.xml · nonDerivative · entry 5 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,331 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F5 · price: Represents volume-weighted average price of sales of 370 shares of Company stock on July 13, 2020 at prices ranging from $624.08 to $624.77. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on July 13, 2020 at each separate price. Read SEC document |
| July 13, 2020 Filed Jul 15, 2020 20:51 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 740 | $623.66 | $461,508.40 |
DisclosureSEC source: 0001708138-20-000087 · edgardoc.xml · nonDerivative · entry 4 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,701 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F4 · price: Represents volume-weighted average price of sales of 740 shares of Company stock on July 13, 2020 at prices ranging from $623.01 to $623.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on July 13, 2020 at each separate price. Read SEC document |
| July 13, 2020 Filed Jul 15, 2020 20:51 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 333 | $622.74 | $207,372.42 |
DisclosureSEC source: 0001708138-20-000087 · edgardoc.xml · nonDerivative · entry 3 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,441 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F3 · price: Represents volume-weighted average price of sales of 333 shares of Company stock on July 13, 2020 at prices ranging from $622.46 to $622.84. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on July 13, 2020 at each separate price. Read SEC document |
| July 13, 2020 Filed Jul 15, 2020 20:51 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 81 | $621.98 | $50,380.38 |
DisclosureSEC source: 0001708138-20-000087 · edgardoc.xml · nonDerivative · entry 2 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,774 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| July 13, 2020 Filed Jul 15, 2020 20:51 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 96 | $620.64 | $59,581.44 |
DisclosureSEC source: 0001708138-20-000087 · edgardoc.xml · nonDerivative · entry 1 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,855 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F2 · price: Represents volume-weighted average price of sales of 96 shares of Company stock on July 13, 2020 at prices ranging from $620.64 to $620.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on July 13, 2020 at each separate price. Read SEC document |
| January 27, 2020 Filed Jan 28, 2020 22:06 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 214 | $343.02 | $73,406.28 |
DisclosureSEC source: 0001237899-20-000006 · edgardoc.xml · nonDerivative · entry 8 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,951 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F9 · price: Represents volume-weighted average price of sales of 214 shares of Company stock on January 27, 2020 at prices ranging from $343.00 to $343.02. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on January 27, 2020 at each separate price. Read SEC document |
| January 27, 2020 Filed Jan 28, 2020 22:06 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,399 | $342.44 | $479,073.56 |
DisclosureSEC source: 0001237899-20-000006 · edgardoc.xml · nonDerivative · entry 7 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,165 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F8 · price: Represents volume-weighted average price of sales of 1,399 shares of Company stock on January 27, 2020 at prices ranging from $342.00 to $342.88. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on January 27, 2020 at each separate price. Read SEC document |
| January 27, 2020 Filed Jan 28, 2020 22:06 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 3,283 | $341.58 | $1,121,407.14 |
DisclosureSEC source: 0001237899-20-000006 · edgardoc.xml · nonDerivative · entry 6 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,564 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F7 · price: Represents volume-weighted average price of sales of 3,283 shares of Company stock on January 27, 2020 at prices ranging from $341.03 to $341.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on January 27, 2020 at each separate price. Read SEC document |
| January 27, 2020 Filed Jan 28, 2020 22:06 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,355 | $340.56 | $461,458.80 |
DisclosureSEC source: 0001237899-20-000006 · edgardoc.xml · nonDerivative · entry 5 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,847 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F6 · price: Represents volume-weighted average price of sales of 1,355 shares of Company stock on January 27, 2020 at prices ranging from $340.05 to $340.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on January 27, 2020 at each separate price. Read SEC document |
| January 27, 2020 Filed Jan 28, 2020 22:06 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 567 | $339.37 | $192,422.79 |
DisclosureSEC source: 0001237899-20-000006 · edgardoc.xml · nonDerivative · entry 4 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,202 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F5 · price: Represents volume-weighted average price of sales of 567 shares of Company stock on January 27, 2020 at prices ranging from $339.01 to $339.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on January 27, 2020 at each separate price. Read SEC document |
| January 27, 2020 Filed Jan 28, 2020 22:06 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 712 | $338.54 | $241,040.48 |
DisclosureSEC source: 0001237899-20-000006 · edgardoc.xml · nonDerivative · entry 3 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,769 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F4 · price: Represents volume-weighted average price of sales of 712 shares of Company stock on January 27, 2020 at prices ranging from $338.07 to $338.93. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on January 27, 2020 at each separate price. Read SEC document |
| January 27, 2020 Filed Jan 28, 2020 22:06 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 270 | $337.46 | $91,114.20 |
DisclosureSEC source: 0001237899-20-000006 · edgardoc.xml · nonDerivative · entry 2 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,481 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F3 · price: Represents volume-weighted average price of sales of 270 shares of Company stock on January 27, 2020 at prices ranging from $337.01 to $337.95. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on January 27, 2020 at each separate price. Read SEC document |
| January 27, 2020 Filed Jan 28, 2020 22:06 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 200 | $336.78 | $67,356.00 |
DisclosureSEC source: 0001237899-20-000006 · edgardoc.xml · nonDerivative · entry 1 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,751 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F2 · price: Represents volume-weighted average price of sales of 200 shares of Company stock on January 27, 2020 at prices ranging from $336.55 to $336.93. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on January 27, 2020 at each separate price. Read SEC document |
| December 11, 2019 Filed Dec 13, 2019 21:41 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 24,500 | $0.00 Strike: $372.46 | $0.00 |
DisclosureSEC source: 0001237899-19-000036 · edgardoc.xml · derivative · entry 4 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,500 Underlying: Common Stock · 24,500 shares Expires 2029-12-11 F3 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| December 11, 2019 Filed Dec 13, 2019 21:41 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001237899-19-000036 · edgardoc.xml · nonDerivative · entry 2 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,951 F2 · kind: Award of Restricted Stock under the Amended and Restated 2014 Long-Term Incentive Plan that vests in its entirety on December 11, 2023. Read SEC document |
| December 11, 2019 Filed Dec 13, 2019 21:41 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantCommon Stock | 2,625 | $0.00 | $0.00 |
DisclosureSEC source: 0001237899-19-000036 · edgardoc.xml · nonDerivative · entry 1 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,951 F1 · kind: Award of Restricted Stock under the Amended and Restated 2014 Long-Term Incentive Plan that vests 50% on December 11, 2021 and 50% on December 11, 2023. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.